Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection

Journal of Digestive Diseases

Volumn 10, Issue 2, 2009, Pages 145-148

  Takemoto, Ryosuke ^a   Nakamuta, Makoto ^a   Aoyagi, Yoko ^a   Fujino, Tatsuya ^a   Yasutake, Kenichiro ^a   Koga, Kotaro ^a   Yoshimoto, Tsuyoshi ^a   Miyahara, Toshihiko ^a   Fukuizumi, Kunitaka ^a   Wada, Yoshiyuki ^a   Takami, Yuko ^a   Saitsu, Hideki ^a   Harada, Naohiko ^a   Nakashima, Manabu ^b   Enjoji, Munechika ^b  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; FibroScan; Fibrosis

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 4; HYALURONIC ACID; INTERFERON; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER HISTOLOGY; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; VALIDITY;

AGED; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED;

EID: 65449182673     PISSN: 17512972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2009.00377.x     Document Type: Article

References (22)

1. Thomas DL, Seef LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-98.
2. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of prospective nationwide survey. Hepatology 2000; 32: 477-81.
3. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Eng J Med 2001; 344: 495-500.
4. Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
5. Colloredo G, Guido M, Sonzogni A et al. Impact of liver biopsy size on histological evaluation of choric viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
6. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
7. Siddique I, El-Naga HA, Madda JP et al. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427-38.
8. Friedman LS. Controversies in liver biopsy: Who, where, when, how, why? Curr Gastroenterol Rep 2004; 6: 30-6.
9. Sandrin L, Tanter M, Gennisson JL et al. Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002; 49: 436-46.
10. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: A new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.
11. Saito H, Tada S, Nakamoto N et al. Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res 2004; 29: 97-103.
12. Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
13. Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.
14. Ogawa E, Furusho N, Toyoda K et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007; 37: 1002-10.
15. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: A systematic review of diagnostic test accuracy. Am J Gastroenterol 2007; 102: 2589-600.
16. Ichida F, Tsuji T, Omata M et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Com 1996; 6: 112-19.
17. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol 1998; 15: 246-58.
18. Gheorghe L, Grigorescu M, Iacob S et al. Effectiveness and tolerability of pegylated interferon α-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: From clinical trials to clinical practice. Rom J Gastroenterol 2005; 14: 109-15.
19. Marrache F, Consigny Y, Ripault MP et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005; 12: 421-8.
20. Helbling B, Jochum W, Stamenic I et al. HCV-related advanced fibrosis/ cirrhosis: Randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762-9.
21. Zheng M, Cai WM, Weng HL et al. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002; 8: 1073-6.
22. Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004; 41: 935-42.